Literature DB >> 14999471

Diagnostic role of galectin-3 in follicular thyroid tumors.

Marco Volante, Francesca Bozzalla-Cassione, Fabio Orlandi, Mauro Papotti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14999471     DOI： 10.1007/s00428-004-0993-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  17 in total

1.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

Authors:  T G Kroll; P Sarraf; L Pecciarini; C J Chen; E Mueller; B M Spiegelman; J A Fletcher
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

2.  Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules.

Authors:  Armando Bartolazzi; Mauro Papotti; Fabio Orlandi
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

3.  Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions.

Authors:  Marille E Herrmann; Virginia A LiVolsi; Theresa L Pasha; Shelley A Roberts; Eva M Wojcik; Zubair W Baloch
Journal:  Arch Pathol Lab Med       Date:  2002-06       Impact factor: 5.534

4.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions.

Authors:  A Bartolazzi; A Gasbarri; M Papotti; G Bussolati; T Lucante; A Khan; H Inohara; F Marandino; F Orlandi; F Nardi; A Vecchione; R Tecce; O Larsson
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

5.  Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins.

Authors:  E Fonseca; J M Nesland; J Höie; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  1997-03       Impact factor: 4.064

6.  Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.

Authors:  D Cvejic; S Savin; I Paunovic; S Tatic; M Havelka; J Sinadinovic
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

7.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors:  Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

8.  Thyroperoxidase immunodetection for the diagnosis of malignancy on fine-needle aspiration of thyroid nodules.

Authors:  J F Henry; A Denizot; A Porcelli; M Villafane; P Zoro; S Garcia; C De Micco
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

9.  Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.

Authors:  Luciane Martins; Sílvia E Matsuo; Kátia N Ebina; Marco Aurélio V Kulcsar; Celso U M Friguglietti; Edna T Kimura
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

10.  Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents.

Authors:  Marek Niedziela; Jaroslaw Maceluch; Eugeniusz Korman
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958
View more
  10 in total

1.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

2.  ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

3.  Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Authors:  Figen Barut; Nilufer Onak Kandemir; Sibel Bektas; Burak Bahadir; Sevinc Keser; Sukru Oguz Ozdamar
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

4.  Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia.

Authors:  Bogdan Galusca; Jean Marc Dumollard; Sandrine Lassandre; Alain Niveleau; Jean Michel Prades; Bruno Estour; Michel Peoc'h
Journal:  Virchows Arch       Date:  2005-05-13       Impact factor: 4.064

5.  RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors.

Authors:  He-Yu Zhang; Long Jin; Gail A Stilling; Katharina H Ruebel; Kendra Coonse; Yoshinori Tanizaki; Avraham Raz; Ricardo V Lloyd
Journal:  Endocrine       Date:  2008-11-20       Impact factor: 3.633

6.  Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.

Authors:  Young Joo Park; Soo Heon Kwak; Dong Chul Kim; Haeryoung Kim; Gheeyoung Choe; Do Joon Park; Hak Chul Jang; Seong Hoe Park; Bo Youn Cho; So Yeon Park
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

Review 7.  Extracellular galectin-3 in tumor progression and metastasis.

Authors:  Anneliese Fortuna-Costa; Angélica M Gomes; Eliene O Kozlowski; Mariana P Stelling; Mauro S G Pavão
Journal:  Front Oncol       Date:  2014-06-16       Impact factor: 6.244

8.  Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis.

Authors:  Weiwei Tang; Congwei Huang; Chongyin Tang; Jin Xu; Hanjin Wang
Journal:  Onco Targets Ther       Date:  2016-01-22       Impact factor: 4.147

9.  The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature.

Authors:  Raymon H Grogan; Elliot J Mitmaker; Orlo H Clark
Journal:  Cancers (Basel)       Date:  2010-05-20       Impact factor: 6.639

Review 10.  Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner.

Authors:  Seok-Jun Kim; Kyung-Hee Chun
Journal:  BMB Rep       Date:  2020-04       Impact factor: 4.778
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.